A Study Evaluating the Safety and Efficacy of AUR108 in Patients With Relapsed Advanced Lymphomas (ASHA-1)

NCT05984147 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Advanced Lymphomas

Interventions

DRUG: AUR108

Sponsor

Aurigene Discovery Technologies Limited